Sorrento Publishes an Abivertinib Teaser Entitled “Abivertinib – a Franchise Oral Therapeutic For Cancer, Covid-19 And Autoimmune Diseases

On November 29, 2021 Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") reported the publication of a Teaser titled "Abivertinib – a Franchise Oral Therapeutic for Cancer, COVID-19 and Autoimmune Diseases" ("Abivertinib Teaser"). Sorrento intends to use the Abivertinib Teaser to engage in discussions with interested third parties in the pharmaceutical industry (Press release, Sorrento Therapeutics, NOV 29, 2021, View Source [SID1234596192]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The key highlights of the Abivertinib Teaser are outlined below:

Abivertinib for COVID-19 (Two Phase 2 trials Completed)
100 mg once-a-day oral capsule for hospitalized COVID-19 patients
US trial (N=96) and Brazil trial (N=400)
For Severe Ordinal Scale (OS) Category 5 COVID-19 Patients ("At-Risk Group") identified to be beneficial with Abivertinib treatment at Day 28 (D28):

Abivertinib reduced the risk of death or respiratory failure:

by 48% in US trial (death or respiratory failure: 21.7% in the Abivertinib group vs. 41.7% in the placebo plus Standard of Care (SoC) control group)
by 45% in Brazil trial (death or respiratory failure: 30.4% Abivertinib vs. 55.6% placebo plus SoC controls)

Abivertinib reduced the ICU stay:

by 2 days in the US trial (8.6 days average stay in ICU in Abivertinib group vs. 10.6 days in placebo plus SoC control group)

Abivertinib for Cancer Indications
NSCLC (Pivotal Trial: N=229) – Among 209 response evaluable NSCLC patients who developed resistance to first line Tyrosine Kinase Inhibitors (TKIs):

93.3% (n/N: 195/209) subjects achieved tumor shrinkage at target lesions
57.4% (n/N: 120/209) subjects achieved the best ORR (confirmed + unconfirmed
PR)
52.2% (n/N: 109/209) subjects achieved confirmed PR1
24.9 months OS
B-Cell Lymphoma (Phase 1/2 Trial) (as of 08/28/2020)

63.6% ORR (n/N: 14/22)
95.5% DCR (n/N: 21/22)
19.7 Months PFS
Abivertinib – A Broad Pipeline for Cancer, COVID-19 and Autoimmune Diseases ($61B Market)